Neuropharmacology Core

项目摘要/摘要 加州大学天然产物神经科学卓越研究中心(CORE-NPN) 密西西比州药学院(UM)，十年前通过科布雷赠款发起，已经开发出一种 致力于评估天然产品对中枢神经系统影响的多学科团队 (CNS)。Cobre CORE-NPN计划的神经药理学研究核心代表着一个共享的 为生物医学研究人员/用户提供专门服务和神经药理学培训的资源 基于(A)竞争性放射性配基受体结合，(B)调节分子/生化靶标的生物测定 功能(C)基于细胞的表型和功能反应以及(D)体内行为药理学。这是 最初两个核心，体外和体内药理学，在第一阶段和第二阶段，由研究人员大力利用 以及两者之间的强有力的合作。在第三阶段，已经确定这些核心将最好地服务于 将程序作为一个功能单元。此外，到第三阶段结束时，核心预计将主要 可持续，重点是了解铅生物提取物或 纯化的化合物以及它们如何与生物系统相互作用。努力的重点是扩大 核心能力，通过增加可供用户使用的体外和体内检测，从而增加 预计服务的用户数。年内将实施按服务收费/按存储容量使用计费的业务模式 第三阶段，以确保第三阶段之后的可持续性。具体核心服务包括放射性配基结合和功能 大麻素、阿片类和神经肽FFG蛋白偶联受体(GPCRs)以及酶的测定 神经药理信号分析、基于表型神经元细胞培养的分析 小路。此外，Core还提供了一系列急性行为啮齿动物和斑马鱼的检测方法，以评估 天然产物提取物和体内纯化的化合物。新的体外测试和动物模型将继续 为支持用户需求而开发，最终扩大了核心的总体范围和用户基础。 核心定位为成为神经药理服务的领导者基于天然产品和 合成药物开发活动。我们计划通过以下具体目标实现这一目标：1) 通过最新技术加强对COBRE CORE-NPN及其相关社区的研究 设备、尖端技术和科学专长；2)推进发展基础设施 通过不断改进和改进，促进Cobre CORE-NPN研究和相关社区的服务 通过用户输入添加化验。3)通过以下方式加快核心可持续性的长期计划 扩大用户基础、整合按服务收费结构、体制支助和适应 通过监控用户的需求进行更改。

PROJECT SUMMARY/ABSTRACT The Center of Research Excellence in Natural Products Neuroscience (CORE-NPN) at The University of Mississippi School of Pharmacy (UM), initiated ten years ago through a COBRE grant, has developed a multidisciplinary team committed to evaluating the effects of natural products on the central nervous system (CNS). The Neuropharmacology Research Core of the COBRE CORE-NPN program represents a shared resource serving biomedical investigators / users with specialized services and training in neuropharmacological bioassays based on (a) competitive radioligand receptor binding, (b) modulation of molecular/biochemical target functions (c) cell-based phenotypic & functional responses and (d) in vivo behavioral pharmacology. This was originally two Cores, in vitro and in vivo pharmacology, in Phases I and II, with strong utilization by investigators and strong collaboration between the two. In Phase III, it has been determined that these Cores would best serve the program as one functional unit. Furthermore, by the end of Phase III, the Core is projected to be largely sustainable with efforts focused on understanding neuropharmacological properties of lead biological extracts or purified compounds and how they interact with biological systems. Efforts have been focused on expanding the core capabilities by increasing both in vitro and in vivo assays that are available to users, thereby increasing the numbers of projected users served. A fee-for-service/chargeback business model will be implemented during Phase III to ensure sustainability post Phase III. Specific Core services include radioligand binding and functional assays for cannabinoid, opioid, and Neuropeptide FF G protein-coupled receptors (GPCRs), as well as enzyme assays, phenotypic neuronal cell cultures-based assays, and analysis of neuropharmacological signaling pathways. Moreover, the Core offers a battery of acute behavioral rodent and zebrafish assays to evaluate natural product extracts and purified compounds in vivo. New in vitro assays and animal models will continue to be developed to support user needs, which ultimately broadens the overall scope and user-base for the Core. The Core is positioned to become a leader in neuropharmacological services based on natural product and synthetic drug development campaigns. We plan to achieve this through the following Specific Aims: 1) To enhance the research of the COBRE CORE-NPN and the associated community through state-of-the-art equipment, cutting-edge techniques, and scientific expertise; 2) To advance an infrastructure of developmental services to facilitate COBRE CORE-NPN research and the associated community by continual refinement and addition of assays through user input. 3) To accelerate a long-term plan for sustainability of the Core through expansion of the user base, integration of a fee-for-service structure, institutional support, and adaptation to changes by monitoring the needs of the users.